



**Item 7.01. Regulation FD Disclosure**

On April 19, 2010, Eli Lilly and Co. ( Lilly ) and Amylin Pharmaceuticals, Inc ( Amylin ) announced that Lilly submitted the Marketing Authorization Application filing for BYDUREON (exenatide for extended-release injectable suspension) for the treatment of type 2 diabetes to the European Medicines Agency. Alkermes, Inc. ( Alkermes ), Amylin, and Lilly are working together to develop BYDUREON, a subcutaneous injection of exenatide for the treatment of type 2 diabetes that utilizes Alkermes proprietary Medisor<sup>®</sup> technology to create an extended-release injection. BYDUREON is not currently approved by any regulatory agencies. This information shall not be deemed filed for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ALKERMES, INC.**

Date: April 19, 2010

By: /s/ James M. Frates  
James M. Frates  
Senior Vice President, Chief Financial  
Officer and Treasurer